Christopher J Ricketts

List of Publications by Year
in descending order

63 papers	5,588 citations	126708 33 h-index	114278 63 g-index
65 all docs	65 docs citations	65 times ranked	8924 citing authors

#	Article	IF	Citations
1	Differential VHL Mutation Patterns in Bilateral Clear Cell RCC Distinguishes Between Independent Primary Tumors and Contralateral Metastatic Disease. Urology, 2022, 165, 170-177.	0.5	2
2	Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma. Urology, 2021, 149, 89-97.	0.5	22
3	Summary from the Kidney Cancer Associationâ€™s Inaugural Think Thank: Coalition for a Cure. Clinical Genitourinary Cancer, 2021, 19, 167-175.	0.9	4
4	MicroRNA Profiling of Morphologically Heterogeneous Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2021, 12, 5375-5384.	1.2	2
5	Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI. Blood, 2021, 137, 126-137.	0.6	29
6	Comprehensive characterization of Alu â€mediated breakpoints in germline VHL gene deletions and rearrangements in patients from 71 VHL families. Human Mutation, 2021, 42, 520-529.	1.1	6
7	Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. Genes Chromosomes and Cancer, 2021, 60, 434-446.	1.5	10
8	Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydrataseâ€“deficient renal cancer. Science Signaling, 2021, 14, .	1.6	64
9	Multifocal Renal Cell Carcinomas With Somatic IDH2 Mutation: Report of a Previously Undescribed Neoplasm. American Journal of Surgical Pathology, 2021, 45, 137-142.	2.1	5
10	A germline 1;3 translocation disrupting the VHL gene: a novel genetic cause for von Hippel-Lindau. Journal of Medical Genetics, 2020, , jmedgenet-2020-107308.	1.5	8
11	Complexities in estimating the true risk of hereditary leiomyomatosis and renal cell carcinoma and the development of kidney cancer. Cancer, 2020, 126, 3617-3619.	2.0	5
12	Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. Journal of Clinical Oncology, 2020, 38, 1146-1153.	0.8	39
13	Novel renal medullary carcinoma cell lines, <scp>UOK353</scp> and <scp>UOK360</scp>, provide preclinical tools to identify new therapeutic treatments. Genes Chromosomes and Cancer, 2020, 59, 472-483.	1.5	7
14	The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nature Reviews Urology, 2019, 16, 539-552.	1.9	357
15	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell, 2019, 179, 964-983.e31.	13.5	430
16	The Metabolic Basis of Kidney Cancer. Cancer Discovery, 2019, 9, 1006-1021.	7.7	163
17	Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc. Scientific Reports, 2019, 9, 18409.	1.6	10
18	Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, earlyâ€onset disease. Cancer, 2019, 125, 1060-1069.	2.0	28

#	Article	IF	Citations
19	CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors. Urology, 2019, 124, 91-97.	0.5	20
20	Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma. Cell, 2018, 173, 540-542.	13.5	37
21	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	2.9	523
22	Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers. Oncotarget, 2018, 9, 10723-10733.	0.8	35
23	The origin, evolution and route to metastasis of clear cell RCC. Nature Reviews Nephrology, 2018, 14, 538-540.	4.1	6
24	Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma. Genes Chromosomes and Cancer, 2017, 56, 484-492.	1.5	21
25	RCC â€" advances in targeted therapeutics and genomics. Nature Reviews Urology, 2017, 14, 76-78.	1.9	14
26	Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma. Cancer Discovery, 2017, 7, 1221-1223.	7.7	8
27	Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). Genes Chromosomes and Cancer, 2017, 56, 719-729.	1.5	14
28	Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget, 2017, 8, 17628-17642.	0.8	11
29	Patient-specific factors influence somatic variation patterns in von Hippelâ€"Lindau disease renal tumours. Nature Communications, 2016, 7, 11588.	5.8	24
30	Papillary Renal-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 1990-1991.	13.9	3
31	SnapShot: Renal Cell Carcinoma. Cancer Cell, 2016, 29, 610-610.e1.	7.7	35
32	Targeting HIF2Î± in Clear-Cell Renal Cell Carcinoma. Cancer Cell, 2016, 30, 515-517.	7.7	23
33	New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease. Clinical Cancer Research, 2015, 21, 10-17.	3.2	88
34	Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC). PLoS ONE, 2015, 10, e0140257.	1.1	56
35	Targeting ABL1-Mediated Oxidative Stress Adaptation in Fumarate Hydratase-Deficient Cancer. Cancer Cell, 2014, 26, 840-850.	7.7	87
36	The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management. Urology, 2014, 83, 1225-1232.	0.5	40

#	Article	IF	Citations
37	Intratumoral heterogeneity in kidney cancer. Nature Genetics, 2014, 46, 214-215.	9.4	44
38	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. Cancer Cell, 2014, 26, 319-330.	7.7	665
39	Discoveries, therapies and opportunities. Nature Reviews Urology, 2014, 11, 614-616.	1.9	24
40	Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nature Reviews Urology, 2014, 11, 465-475.	1.9	227
41	Tumor-Specific Hypermethylation of Epigenetic Biomarkers, Including SFRP1, Predicts for Poorer Survival in Patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) Project. PLoS ONE, 2014, 9, e85621.	1.1	58
42	A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma. Molecular Cancer Research, 2013, 11, 1061-1071.	1.5	135
43	The metabolic basis of kidney cancer. Seminars in Cancer Biology, 2013, 23, 46-55.	4.3	132
44	New Insights into von Hippel-Lindau Function Highlighted by Investigation of the Trichloroethylene-Induced p.P81S Hotspot Mutation. Journal of the National Cancer Institute, 2013, 105, 1339-1340.	3.0	3
45	<scp>UBE</scp> 2 <scp>QL</scp> 1 is Disrupted by a Constitutional Translocation Associated with Renal Tumor Predisposition and is a Novel Candidate Renal Tumor Suppressor Gene. Human Mutation, 2013, 34, 1650-1661.	1.1	18
46	Metabolic Reprogramming for Producing Energy and Reducing Power in Fumarate Hydratase Null Cells from Hereditary Leiomyomatosis Renal Cell Carcinoma. PLoS ONE, 2013, 8, e72179.	1.1	80
47	Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer. Journal of Urology, 2012, 188, 2063-2071.	0.2	211
48	A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genetics, 2012, 205, 377-390.	0.2	55
49	Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nature Genetics, 2012, 44, 277-284.	9.4	219
50	Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics, 2012, 7, 278-290.	1.3	54
51	Metabolic evaluation of sporadic papillary kidney cancer.. Journal of Clinical Oncology, 2012, 30, 377-377.	0.8	0
52	Genome-Wide DNA Methylation Profiling of CpG Islands in Breast Cancer Identifies Novel Genes Associated with Tumorigenicity. Cancer Research, 2011, 71, 2988-2999.	0.4	141
53	Mutations in FLVCR2 Are Associated with Proliferative Vasculopathy and Hydranencephaly-Hydrocephaly Syndrome (Fowler Syndrome). American Journal of Human Genetics, 2010, 86, 471-478.	2.6	60
54	Tumor risks and genotypeÃ¢Â€Â“phenotypeÃ¢Â€Â“proteotype analysis in 358 patients with germline mutations inSDHBandSDHD. Human Mutation, 2010, 31, 41-51.	1.1	325

#	Article	IF	Citations
55	Subcellular distribution of lowâ€voltage activated Tâ€type Ca²⁺ channel subunits (Ca_v3.1 and Ca_v3.3) in reticular thalamic neurons of the cat. Journal of Neuroscience Research, 2010, 88, 448-460.	1.3	17
56	Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocrine-Related Cancer, 2010, 18, 73-83.	1.6	49
57	Spectrum and Prevalence of FP/TMEM127 Gene Mutations in Pheochromocytomas and Paragangliomas. JAMA - Journal of the American Medical Association, 2010, 304, 2611.	3.8	174
58	Analysis of Germline Variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in Familial and Sporadic Renal Cell Carcinoma. PLoS ONE, 2009, 4, e6037.	1.1	40
59	Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma. Anticancer Research, 2009, 29, 4337-43.	0.5	52
60	Germline SDHB Mutations and Familial Renal Cell Carcinoma. Journal of the National Cancer Institute, 2008, 100, 1260-1262.	3.0	330
61	Familial Non-VHL Clear Cell (Conventional) Renal Cell Carcinoma: Clinical Features, Segregation Analysis, and Mutation Analysis of FLCN. Clinical Cancer Research, 2008, 14, 5925-5930.	3.2	64
62	Sodium-potassium ATPase 1 subunit is a molecular partner of Wolframin, an endoplasmic reticulum protein involved in ER stress. Human Molecular Genetics, 2007, 17, 190-200.	1.4	85
63	Transcriptional Regulation of Cyclin A2 by RASSF1A through the Enhanced Binding of p120E4F to the Cyclin A2 Promoter. Cancer Research, 2005, 65, 2690-2697.	0.4	39